XML 81 R67.htm IDEA: XBRL DOCUMENT v3.19.2
Related Parties Transactions (Details Textual) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Oct. 02, 2018
Apr. 12, 2017
May 06, 2016
Feb. 02, 2019
Nov. 29, 2018
Jun. 27, 2018
Jan. 18, 2018
Sep. 30, 2017
Sep. 28, 2017
Jul. 24, 2017
Jan. 26, 2017
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Dec. 31, 2017
Aug. 25, 2018
May 09, 2018
Sep. 25, 2017
Related Parties Transactions (Textual)                                    
Amount received from BriVision                       $ 7,594,784   $ 7,745,096 $ 4,229,320      
Outstanding loan                       233,000   692,980        
Accrued interest                       11,971   281        
Interest expenses                       129,886 $ 106,854 155,930 103,460      
Common stock new issues                       694,219 80,000 80,000 5,850,000      
Additional paid-in capital                       15,680,674   14,983,714 13,805,936      
Rent expenses                           0        
Related party transactions, description               Pursuant to the Investment and Equity Transfer Agreement, Everfront agreed to purchase 2,000,000 common shares of the Company owned by AsianGene at $1.60 per share in a total amount of $3,200,000, of which $160,000 is due before September 15, 2017 and the remaining amount of $3,040,000 is due before December 15, 2017. AsianGene also agreed to loan the proceeds to the Company for working capital purpose.                    
Aggregate principal amount           $ 250,000                   $ 250,000    
Yuangene Corporation [Member]                                    
Related Parties Transactions (Textual)                                    
Outstanding loan                       $ 926,395            
Related party transactions, description                       The advances bear 0% interest rate and are due on demand.            
Unsecured convertible promissory note [Member]                                    
Related Parties Transactions (Textual)                                    
Accrued interest                       $ 43,467   27,467        
Aggregate principal amount           250,000                   $ 250,000 $ 300,000  
Chairman [Member]                                    
Related Parties Transactions (Textual)                                    
Outstanding loan                       157,140            
Accrued interest                       $ 10,454            
Aggregate working capital                             $ 100      
Interest rate percentage                             0.00%      
Related party transactions, description                       The advances bears interest at 1% per month (or equivalent to 12% per annum) and are due on demand.            
Collaborative Arrangement [Member]                                    
Related Parties Transactions (Textual)                                    
Amount received from BriVision                       $ 100,000,000   100,000,000        
Interest rate percentage                       0.00%            
Outstanding advance                       $ 517,949            
Common stock new issues     $ 900,000             $ 3,000,000                
Due to BioFirst                                   $ 3,000,000
Loan Agreement [Member]                                    
Related Parties Transactions (Textual)                                    
Total commitment       $ 693,000             $ 950,000              
Loan maturity date       Feb. 01, 2020             Feb. 01, 2018              
Loan agreement, description                 BioLite Taiwan and BioFirst entered into three loan agreements for a total amount of NTD$27,800,000, equivalent to $900,720, to meet its working capital needs. Under the terms of the loan agreements, the loans bear interest at 1% per month (or equivalent to 12% per annum). BioLite Taiwan repaid NTD$7,500,000, equivalent to $243,000, of the loan in 2018. The remaining balance was NTD$20,300,000, equivalent to $657,720 with the interest rate and term remain unchanged. The three loans will be matured on September 27, 2019, October 30, 2019, and November 12, 2019, respectively.   The loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to pay interest monthly to the lender.              
Outstanding loan                       657,720   663,810        
Accrued interest                       146,274   127,976        
Interest expenses                       19,472 28,500          
Loan Agreement [Member] | BriVision and BioFirst Agreement [Member]                                    
Related Parties Transactions (Textual)                                    
Interest expenses                       11,710 9,500          
Asiangene Corporation [Member]                                    
Related Parties Transactions (Textual)                                    
Amount received from BriVision                           160,000 $ 160,000      
Outstanding loan                       160,000   160,000        
Accrued interest                       17,600   12,866        
Interest expenses                       $ 4,734 3,945 18,411        
Interest rate percentage                       0.00%            
Yuangene Corporation [Member]                                    
Related Parties Transactions (Textual)                                    
Amount received from BriVision                           92,690 3,000      
Outstanding loan                       $ 50,000   50,000        
Accrued interest                       7,200   5,721        
Interest expenses                       1,479 1,200 5,721        
Aggregate working capital             $ 50,000         $ 42,690   $ 42,690        
Interest rate percentage                       0.00%   0.00%        
Additional paid-in capital               $ 70,000                    
Related party transactions, description             Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to pay interest monthly to the lender. The maturity date of this loan is January 19, 2019.                      
Keypoint Technology Ltd [Member] | Unsecured convertible promissory note [Member]                                    
Related Parties Transactions (Textual)                                    
Amount received from BriVision           $ 250,000                        
Interest expenses                       $ 5,000 0 $ 10,222 0      
Interest rate percentage           8.00%                        
Yoshinobu Odaira [Member] | Unsecured convertible promissory note [Member]                                    
Related Parties Transactions (Textual)                                    
Amount received from BriVision         $ 250,000                          
Interest expenses                       5,000 0 1,778 0      
Interest rate percentage         8.00%                          
Loan Agreement One [Member]                                    
Related Parties Transactions (Textual)                                    
Loan maturity date   May 11, 2019                                
Loan agreement, description   BioLite BVI and BioFirst entered into a loan agreement for NTD$30,000,000, equivalent to $972,000 to meet its working capital needs. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum). BioLite BVI and BioFirst extended the loan with the same interest rate and amount for one year.                                
Outstanding loan                       972,000   981,000        
Accrued interest                       250,771   222,000        
Interest expenses                       $ 28,771 $ 29,978          
BioFirst Corporation [Member]                                    
Related Parties Transactions (Textual)                                    
Amount received from BriVision                           4,151,301 3,957,000      
Interest expenses                             103,460      
Aggregate working capital                             $ 7,000      
Interest rate percentage                             0.00%      
Kimho Consultants Co., Ltd [Member]                                    
Related Parties Transactions (Textual)                                    
Stock based compensation expenses                             $ 90,000      
Euro-Asia Agreement [Member]                                    
Related Parties Transactions (Textual)                                    
Stock based compensation expenses                           0 60,000      
LionGene Corporation (the "LionGene") [Member]                                    
Related Parties Transactions (Textual)                                    
One-time consulting service                             70,000      
BioKey [Member]                                    
Related Parties Transactions (Textual)                                    
Interest expenses                                  
Additional paid-in capital                           82,265        
Monthly base rent $ 800                                  
Rent expenses                           $ 2,400 $ 0